Cargando…

Global phosphoproteome analysis of human bone marrow reveals predictive phosphorylation markers for the treatment of acute myeloid leukemia with quizartinib

Detalles Bibliográficos
Autores principales:	Schaab, C, Oppermann, F S, Klammer, M, Pfeifer, H, Tebbe, A, Oellerich, T, Krauter, J, Levis, M, Perl, A E, Daub, H, Steffen, B, Godl, K, Serve, H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3948157/ https://www.ncbi.nlm.nih.gov/pubmed/24247654 http://dx.doi.org/10.1038/leu.2013.347

Ejemplares similares

Identifying differentially regulated subnetworks from phosphoproteomic data
por: Klammer, Martin, et al.
Publicado: (2010)

Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells
por: Roolf, Catrin, et al.
Publicado: (2017)

Concentration–QTc analysis of quizartinib in patients with relapsed/refractory acute myeloid leukemia
por: Kang, Dongwoo, et al.
Publicado: (2021)

Population Pharmacokinetic Analysis of Quizartinib in Healthy Volunteers and Patients With Relapsed/Refractory Acute Myeloid Leukemia
por: Kang, Dongwoo, et al.
Publicado: (2020)

Quizartinib (AC220): a promising option for acute myeloid leukemia
por: Zhou, Fang, et al.
Publicado: (2019)

Combating drug resistance in acute myeloid leukaemia by drug rotations: the effects of quizartinib and pexidartinib
por: Yang, Jingmei, et al.
Publicado: (2021)

Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells
por: Aikawa, Tomoya, et al.
Publicado: (2020)

Effect of Food on the Pharmacokinetics of Quizartinib
por: Li, Jianke, et al.
Publicado: (2020)

Pareto Optimization Identifies Diverse Set of Phosphorylation Signatures Predicting Response to Treatment with Dasatinib
por: Klammer, Martin, et al.
Publicado: (2015)

A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome
por: Swaminathan, Mahesh, et al.
Publicado: (2021)

Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia
por: Altman, Jessica K., et al.
Publicado: (2017)

S137: IMPACT OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN FIRST COMPLETE REMISSION PLUS FLT3 INHIBITION WITH QUIZARTINIB IN ACUTE MYELOID LEUKEMIA WITH FLT3-ITD: RESULTS FROM QUANTUM-FIRST
por: Schlenk, Richard, et al.
Publicado: (2023)

Metabolic Plasticity of Acute Myeloid Leukemia
por: Kreitz, Johanna, et al.
Publicado: (2019)

Sleeping through the storm: Preventing myelosuppression with quizartinib
por: Taylor, Samuel J., et al.
Publicado: (2017)

Repurposing of Ibrutinib and Quizartinib as potent inhibitors of necroptosis
por: Huang, Fangmin, et al.
Publicado: (2023)

Quantitative Phosphoproteomics Analysis of ERBB3/ERBB4 Signaling
por: Wandinger, Sebastian K., et al.
Publicado: (2016)

Proteomic and phosphoproteomic landscapes of acute myeloid leukemia
por: Kramer, Michael H., et al.
Publicado: (2022)

Profile of Quizartinib for the Treatment of Adult Patients with Relapsed/Refractory FLT3-ITD-Positive Acute Myeloid Leukemia: Evidence to Date
por: Fletcher, Luke, et al.
Publicado: (2020)

Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients
por: Dennis, Mike, et al.
Publicado: (2021)

Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports
por: Martínez-Cuadrón, David, et al.
Publicado: (2020)

Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5-and hypoxia-dependent upregulation of AXL
por: Dumas, Pierre-Yves, et al.
Publicado: (2019)

Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant
por: Sandmaier, Brenda M., et al.
Publicado: (2017)

Proteome and Phosphoproteome Changes Associated with Prognosis in Acute Myeloid Leukemia
por: Aasebø, Elise, et al.
Publicado: (2020)

Relapse surveillance of acute myeloid leukemia patients in first remission after consolidation chemotherapy: diagnostic value of regular bone marrow aspirations
por: Koschade, Sebastian E., et al.
Publicado: (2022)

Phosphoproteomics Sample Preparation Impacts Biological Interpretation of Phosphorylation Signaling Outcomes
por: Sampadi, Bharath, et al.
Publicado: (2021)

Clostridioides difficile Phosphoproteomics Shows an Expansion of Phosphorylated Proteins in Stationary Growth Phase
por: Smits, Wiep Klaas, et al.
Publicado: (2022)

Phosphoproteomic analysis identifies insulin enhancement of discoidin domain receptor 2 phosphorylation
por: Iwai, Leo K., et al.
Publicado: (2013)

Global Effects of Kinase Inhibitors on Signaling Networks Revealed by Quantitative Phosphoproteomics
por: Pan, Cuiping, et al.
Publicado: (2009)

Crystal Structure of the FLT3 Kinase Domain Bound to the Inhibitor Quizartinib (AC220)
por: Zorn, Julie A., et al.
Publicado: (2015)

Synergistic effect of a novel autophagy inhibitor and Quizartinib enhances cancer cell death
por: Ouchida, Amanda Tomie, et al.
Publicado: (2018)

Identification of Significant Features by the Global Mean Rank Test
por: Klammer, Martin, et al.
Publicado: (2014)

Reconstructing phosphorylation signalling networks from quantitative phosphoproteomic data
por: Invergo, Brandon M., et al.
Publicado: (2018)

Profiling the Human Phosphoproteome to Estimate the True Extent of Protein Phosphorylation
por: Kalyuzhnyy, Anton, et al.
Publicado: (2022)

Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance: In vitro and in vivo studies
por: Li, Jun, et al.
Publicado: (2017)

Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms
por: Patel, Ami B., et al.
Publicado: (2020)

Fetal calf serum heat inactivation and lipopolysaccharide contamination influence the human T lymphoblast proteome and phosphoproteome
por: Rahman, Hazir, et al.
Publicado: (2011)

Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD
por: Jaramillo, Sonia, et al.
Publicado: (2023)

Comparative phosphoproteomics reveals evolutionary and functional conservation of phosphorylation across eukaryotes
por: Boekhorst, Jos, et al.
Publicado: (2008)

Integrating Phosphoproteomics and Bioinformatics to Study Brassinosteroid-Regulated Phosphorylation Dynamics in Arabidopsis
por: Lin, Li-Ling, et al.
Publicado: (2015)

Conservation of kinase-phosphorylation site pairings: Evidence for an evolutionarily dynamic phosphoproteome
por: McDonald, Megan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0vruajs9mrh8mf5t91d08sjb6n